[Form 4] AdaptHealth Corp. Insider Trading Activity

Rhea-AI Filing Summary

AdaptHealth Corp. (AHCO) – Form 4 filing overview:

• Reporting person: Diana L. Nole, listed as a Director of AdaptHealth Corp.
• Transaction date: 06/26/2025.
• Security: Common Stock.
• Transaction type & size: Acquisition of 21,346 shares (code “A”) at a reported price of $0 per share.
• Post-transaction holdings: 33,045 shares held directly.
• Form signing date: 06/30/2025, executed by attorney-in-fact Richard Rew.

No derivative securities were reported and no sales were disclosed. The filing reflects an increase in insider ownership, which may be interpreted by some investors as a sign of board-level confidence, although the dollar value and context of the grant are not provided in the document.

Positive

• Director-level acquisition of 21,346 shares increases insider ownership to 33,045 shares, providing a modest alignment signal for shareholders.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director adds 21.3k shares at $0; modest size, mildly positive sentiment, limited financial impact.

The Form 4 shows Director Diana L. Nole receiving 21,346 AHCO common shares for no consideration, boosting her direct stake to 33,045 shares. While insider acquisitions can be viewed favorably, the zero-cost nature suggests an equity grant rather than an open-market purchase, limiting the signal strength regarding valuation. The amount is small relative to AdaptHealth’s public float, so market impact should be minimal. Overall, this is informational and slightly positive for sentiment, but not materially transformative for the investment thesis.

Portfolio Manager

TL;DR: Small, cost-free stock grant to director—neutral for portfolio weighting, minor positive for governance alignment.

From a portfolio standpoint, the addition of 21k shares to a director’s holding marginally increases insider alignment, which is good governance practice. However, with no cash outlay and limited scale versus AHCO’s daily trading volume, I do not expect pricing repercussions. I would classify this as routine board compensation disclosure rather than a catalyst.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nole Diana L

(Last) (First) (Middle)

C/O ADAPTHEALTH LLC

555 EAST NORTH LANE, SUITE 5075

(Street)

CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		21,346	A	$0	33,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Richard Rew, as attorney-in-fact for Diana L. Nole	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in AdaptHealth Corp. (AHCO) Form 4?

The filing relates to Diana L. Nole, who is listed as a Director of AdaptHealth Corp.

How many AHCO shares were acquired in the reported transaction?

A total of 21,346 common shares were acquired.

What is the insider’s total AHCO shareholding after the transaction?

Following the acquisition, the insider directly owns 33,045 AHCO shares.

What was the reported price per share for the acquisition?

The Form 4 lists a price of $0 per share, indicating a cost-free share grant or award.

When did the transaction take place and when was the Form 4 signed?

The transaction date is 06/26/2025 and the form was signed on 06/30/2025.